Mortality after PCI to the unprotected left main stem (UPLMS) is higher among emergency and urgent cases than elective cases and it is especially high among patients with cardiogenic shock. Following PCI, however, the dominant cause of death is noncardiovascular.
Introduction
Improved stent technology, the de novo presentation of unprotected left main stem (UPLMS) coronary disease at primary percutaneous coronary intervention (PPCI) and evidence from randomised trials reporting good outcomes among higher risk patients has increased the number of patients who receive PCI to the UPLMS [1] [2] [3] . Among emergent, urgent and elective cases of UPLMS PCI, procedural success is high with evidence of over 95%
technical success and excellent short-term outcomes [4] .
However, there is a paucity of representative data regarding the longer-term outcomes following UPLMS PCI. In part, this is due to the inherent bias of small observational cohorts and difficulty in generalising results from the highly selected cohorts recruited into randomised trials, but also because long-term survival studies of UPLMS PCI typically report all-cause mortality [5, 6] . The latter point is of particular importance when, nowadays, the dominant cause of death after PCI is non-cardiovascular and if not accounted for, the efficacy of UPLMS PCI may be underestimated.
Whilst cause-specific mortality records can help ascertain the effect of an intervention on cardiovascular outcomes, this approach has its limitations. Cause-specific mortality records may be difficult to ascertain and when available are limited to trials or if obtained from administrative data can be biased by misclassification of the cause of death [7] . An alternative method to estimate cause-specific outcomes is relative survival, which adjusts for the expected rates of death in the general population. Using a relative survival approach and all cases of UPLMS PCI within the United Kingdom health care system, we aimed to report the rates of relative survival and then quantify the determinants of excess mortality among emergent, urgent and elective cases of UPLMS PCI. To achieve this, we matched cases of To minimise bias due to the inclusion of patients with cardiogenic shock in the STEMI group, we subdivided STEMI cases into those with (STEMI+CS) and without cardiogenic shock (STEMI-CS); both groups only included patients who received primary PCI. The diagnosis of cardiogenic shock was clinical and included a systolic blood pressure <100 mmHg, pulse >100 bpm, in a patient who was cool and clammy or requiring inotropes, intra-aortic balloon pump or other cardiopulmonary support. 
Methods

Patients, setting and inclusion criteria
Mortality and follow up
All-cause mortality data for UPLMS PCI cases were extracted through linkage to the Office for National Statistics using each patient's unique pseudonymised National Health Service number. Patients were followed-up for their vital status up to 5 years after PCI, with censoring at the end of follow-up on 1st July, 2014 (Figure 1a , Appendix). Survival time was defined as the duration between the date of the procedure and the date of death or censoring.
Relative survival
Relative survival was defined as the observed survival among cases of UPLMS PCI divided by the expected survival of the comparable United Kingdom populace and expressed as relative survival rates (RSR) [11] . A relative survival rate of 100% implies that cases of UPLMS PCI have survival rates equal to that of the matched disease free background population. Observed survival was estimated using the actuarial method which calculates the observed survival in time intervals from the effective number of patients at risk in that particular interval and the expected survival by the Ederer II method [11] . For expected survival, country-specific population mortality rates of the United Kingdom were based on life tables from the Office for National Statistics matched to the cohort by single year of age, sex and year of procedure.
Excess mortality
Excess mortality provides a measure of the additional hazard associated with a procedure or treatment and is expressed as a rate ratio (EMRR). Evidence of excess mortality is observed 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 to 32.4%) ( Figure 5 ).
Excess mortality by age, sex and year
For CSA, there was no evidence of excess mortality by age, sex or year of diagnosis. There was, however, significant excess mortality with increasing age (>75 compared with <55 pre-procedural TIMI flow in the infarct related artery and the necessity for pre-procedural ventilation, but was associated with an improvement of about 50% with multivessel PCI.
Given that trials testing the efficacy of the intra-aortic balloon pump have failed to reach their primary endpoints and that there is insufficient evidence for the use of percutaneous assist devices, a greater focus on technologies which support the myocardium (thereby allowing optimal infarct and non-infarct related PCI), improved stent design and enhanced operator experience is needed [16] .
Whereas, for elective cases of UPLMS PCI, attention to co-morbidities (previous MI, diabetes and renal failure), optimisation of left ventricular systolic function and careful evaluation of pre-procedural stenosis severity (using IVUS or FFR) is likely to be key to maintaining the present rates of survival. Addressing these factors and using them to help predict a patients' clinical outcome will provide the opportunity for clinicians to discuss in greater detail the risks and benefits of the intended procedure. However, as survival rates are already very high among this group, future absolute gains are likely to be small.
For NSTEACS, factors that negatively impacted on long-term survival were prior myocardial infarction, diabetes, LMS stenosis >50%, moderate and poor left ventricular systolic function, renal failure, cardiogenic shock and the requirement for mechanical ventilation. As for elective cases, the use of IVUS and FFR was associated with a more than 50% reduction in excess mortality. Although our study design cannot determine a cause and effect relationship, this observation supports guideline recommendations that careful attention to the coronary anatomy and stent deployment are central to good outcomes. Even so, it is 
Strengths and limitations
Even though relative survival and excess mortality are novel concepts for the evaluation of cardiovascular outcomes, these techniques are well established in cancer epidemiology.
Relative survival is an underused tool in cardiovascular outcome reporting [8] , which in an era of evidence-based practice and an ageing 'survivorship' population merits further attention. The use of relative survival for this study has allowed higher resolution estimation of survival and excess deaths specifically due to UPLMS disease and its percutaneous treatment without requiring potentially unreliable 'cause of death' data.
Whilst this study has other strengths, including the size and quality of data, there were Selection bias may have been introduced through the identification and consent of patients, which may lead to a healthier cohort than expected.
Conclusions
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